查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1753886

2025 年至 2033 年癌症生物標記市場報告（按分析技術、生物分子、癌症類型、應用、最終用戶和地區分類）

Cancer Biomarkers Market Report by Profiling Technology, Biomolecule, Cancer Type, Application, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球癌症生物標記市場規模達313億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到895億美元，2025-2033年期間的複合年成長率（CAGR）為11.09%。癌症發生率的上升、個人化醫療的進步、基因組學、蛋白質組學和生物資訊學等技術的重大創新、伴隨診斷需求的不斷成長以及人口老化的加劇，是推動市場發展的主要因素。目前，受先進的醫療基礎設施和不斷增加的研究計劃的推動，北美佔據最大的市場佔有率。

癌症生物標記是存在於體內的特定分子或物質，能夠提供有關癌症存在、進展或特徵的寶貴資訊。這些生物標記在腫瘤學領域中發揮著至關重要的作用，有助於各種癌症的早期發現、診斷、治療監測和預後。它們通常存在於血液、尿液、組織或其他體液中。癌症生物標記的識別和分析涉及基因組學、蛋白質組學和代謝組學等先進技術。這些技術使研究人員和醫療保健專業人員能夠檢測到分子水平的細微變化，從而深入了解癌症的發展及其對治療的反應。透過測量特定生物標記的水平，臨床醫生可以根據個別患者制定治療方案，從而獲得更有針對性的治療方案並改善療效。

全球各類癌症的發生率不斷上升，這是一個重要的促進因素。隨著癌症病例數的成長，對生物標記等精準早期診斷工具的需求也日益成長。此外，生物標記提供了非侵入性的癌症檢測和監測方法，減輕了患者的不適感，並使其能夠進行頻繁的評估。這種便利性正在推動患者接受和臨床應用。此外，早期檢測對於提高存活率至關重要。癌症生物標記能夠在癌症早期階段發現，從而能夠及時干預並可能獲得治癒性治療。此外，伴隨診斷的需求有助於確定患者最有效的治療方法，這也促進了癌症生物標記市場的成長。同時，全球老化人口更容易罹患癌症。這種人口趨勢推動了對改進診斷和治療方法的需求，而生物標記在其中發揮關鍵作用。此外，基因組學、蛋白質組學和生物資訊學等技術的快速發展徹底改變了癌症生物標記的發現和分析。這些技術能夠以更高的靈敏度和特異性識別新型生物標記。此外，個人化醫療的轉變也增加了對生物標記的需求，因為它們能夠識別每個患者癌症特有的特定基因、分子和蛋白質組特徵，從而促進有針對性的治療並改善治療結果。

癌症生物標記市場趨勢/促進因素：

全球癌症發生率的上升為市場帶來了積極的前景。生物標記被廣泛用於早期癌症檢測以及治療和管理，以準確可靠地預測療效。同時，由於污染水平上升、吸煙趨勢和不良飲食習慣，肺癌發病率不斷上升，這也促進了市場的成長。此外，基因生物標記發現領域的各種技術進步，例如新一代定序 (NGS)、聚合酶鍊式反應 (PCR)、基因表現譜（微陣列）以及有助於預測癌症治療後復發的人工智慧 (AI)，也為市場成長提供了動力。此外，醫療保健專業人員和患者對早期診斷重要性的認知不斷提高，以及由於缺乏標準診斷而導致的癌症治療向個人化醫療的顯著轉變，也有利於市場的成長。其他因素，包括醫療保健行業的顯著成長、廣泛的研發活動以及政府為加強藥物開發流程而實施的各種舉措，預計將推動全球癌症生物標記市場的成長。

癌症發生率上升

世界衛生組織 (WHO) 報告稱，由於生活方式改變、環境暴露和人口老化等因素，癌症病例負擔日益加重。這種激增的趨勢迫切需要改進診斷工具，以便在癌症早期發現，以實現最有效的治療。癌症生物標記能夠識別細微的分子變化，從而實現早期發現和風險評估。這使得醫療保健專業人員能夠制定個人化治療方案，最佳化患者預後。隨著癌症盛行率持續上升，對生物標記等精準高效的診斷解決方案的需求預計將持續上升。

個人化醫療的進展

每種癌症都是獨一無二的，由獨特的基因和分子特徵所驅動。這種複雜性需要針對個別癌症具體屬性的客製化治療方法。生物標記為了解這些複雜性打開了一扇窗口，使臨床醫生能夠選擇針對驅動疾病的精確分子變異的療法。透過最大限度地減少治療選擇中的反覆試驗，個人化醫療可以提高療效並減少副作用。由於能夠快速分析患者基因和分子譜的先進技術的出現，這種方法越來越受到關注。隨著個人化醫療日益受到重視，對用於指導治療決策的生物標記的需求將持續成長。預計這將擴大癌症生物標記的市場規模。

重大技術創新

新一代定序、質譜和微陣列分析等高通量技術的出現，大大提升了我們識別和分析潛在生物標記的能力。這些方法能夠識別指示不同癌症類型的特定基因突變、表觀遺傳學變化和蛋白質表現模式。此外，生物資訊學工具有助於解讀海量資料集，從而發現新的候選生物標記。這些技術進步不僅加快了生物標記的發現速度，還提高了其靈敏度和特異性，使其在臨床應用中更加可靠。隨著技術的不斷發展，預計癌症診斷解決方案的數量將不斷擴大，從而進一步改變癌症生物標記的市場前景。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球癌症生物標記市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：透過分析技術

  • 歐米克技術公司
  • 影像技術
  • 免疫測定
  • 細胞遺傳學

第7章：市場區隔：依生物分子

  • 基因生物標記
  • 蛋白質生物標記
  • 糖生物標記

第8章：市場區隔：依癌症類型

  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 胃癌
  • 其他

第9章：市場區隔：依應用

  • 診斷
  • 預測
  • 風險評估
  • 藥物研發
  • 其他

第10章：市場區隔：依最終用戶

  • 醫院
  • 學術和研究機構
  • 門診手術中心
  • 診斷實驗室
  • 其他

第 11 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第 12 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 13 章：價值鏈分析

第 14 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 15 章：價格分析

第 16 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Becton Dickinson and Company
    • bioMerieux SA
    • Danaher Corporation
    • F. Hoffmann-La Roche AG
    • General Electric Company
    • Illumina Inc.
    • Qiagen NV
    • Sino Biological Inc.
    • Thermo Fisher Scientific Inc.
Product Code: SR112025A5834

The global cancer biomarkers market size reached USD 31.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 89.5 Billion by 2033, exhibiting a growth rate (CAGR) of 11.09% during 2025-2033. The rising cancer incidences, advancements in personalized medicine, significant innovations in technologies such as genomics, proteomics, and bioinformatics, augmenting demand for companion diagnostics, and increasing aging population some of the major factors propelling the market. At present, North America holds the largest market share, driven by advanced healthcare infrastructure and increasing research initiatives.

Cancer biomarkers are specific molecules or substances that can be found in the body and provide valuable information about the presence, progression, or characteristics of cancer. These biomarkers play a crucial role in the field of oncology by aiding in the early detection, diagnosis, treatment monitoring, and prognosis of various types of cancer. They are typically present in blood, urine, tissues, or other bodily fluids. The identification and analysis of cancer biomarkers involve advanced techniques such as genomics, proteomics, and metabolomics. These techniques enable researchers and healthcare professionals to detect subtle changes at the molecular level, which can provide insights into the development of cancer and its response to treatments. By measuring the levels of specific biomarkers, clinicians can tailor treatment plans to individual patients, leading to more targeted therapies and improved outcomes.

The increasing prevalence of various types of cancers across the globe is a significant driver. As the number of cancer cases grows, the demand for accurate and early diagnostic tools, like biomarkers, intensifies. Additionally, biomarkers offer non-invasive methods of cancer detection and monitoring, reducing patient discomfort and enabling frequent assessments. This convenience is driving both patient acceptance and clinical adoption. Other than this, early detection is crucial for improving survival rates. Cancer biomarkers allow for the detection of cancers at their earliest stages, enabling timely intervention and potentially curative treatments. Besides this, the demand for companion diagnostics, which help determine the most effective treatment for a patient, is fostering the cancer biomarkers market growth. In line with this, the global aging population is more susceptible to cancer. This demographic trend is driving the need for improved diagnostic and therapeutic approaches, in which biomarkers play a pivotal role. Furthermore, rapid advancements in technologies such as genomics, proteomics, and bioinformatics have revolutionized cancer biomarker discovery and analysis. These technologies enable the identification of novel biomarkers with higher sensitivity and specificity. Moreover, the shift toward personalized medicine has escalated the demand for biomarkers as they enable the identification of specific genetic, molecular, and proteomic signatures unique to each patient's cancer, facilitating targeted therapies and improving treatment outcomes.

Cancer Biomarkers Market Trends/Drivers:

The increasing prevalence of cancer across the globe is creating a positive outlook for the market. Biomarkers are widely used for early cancer detection and during treatment and management to accurately and reliably predict outcomes. In line with this, the increasing incidences of lung cancer due to the upsurge in pollution levels, smoking trends and poor ingestion habits is augmenting the market growth. Moreover, various technological advancements in genetic biomarker discovery, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), gene expression profiling (microarray), and the artificial inelegance (AI) that assist in predicting the recurrence of cancer after treatment, are providing an impetus to the market growth. Additionally, the increasing awareness amongst healthcare professionals and patients about the importance of early diagnosis and the significant shift toward personalized medicine for cancer treatment due to the lack of standard diagnosis is favoring the market growth. Other factors, including the significant growth in the healthcare industry, extensive research and development (R&D) activities and the implementation of various government initiatives for enhancing the drug development processes, are anticipated to drive the global cancer biomarkers market toward growth.

Rising Cancer Incidence

The World Health Organization (WHO) reports a growing burden of cancer cases, attributed to factors such as lifestyle changes, environmental exposures, and an aging population. This surge necessitates improved diagnostic tools that can detect cancer at its earliest stages, when treatment is most effective. Cancer biomarkers, with their ability to identify subtle molecular changes, enable early detection and risk assessment. This empowers healthcare professionals to devise tailored treatment plans, optimizing patient outcomes. As cancer prevalence continues to escalate, the demand for accurate and efficient diagnostic solutions like biomarkers is expected to remain on an upward trajectory.

Advancements in Personalized Medicine

Each cancer is unique, driven by distinct genetic and molecular characteristics. This complexity demands tailored treatment approaches that address the specific attributes of an individual's cancer. Biomarkers offer a window into these intricacies, allowing clinicians to select therapies that target the precise molecular alterations driving the disease. By minimizing trial and error in treatment selection, personalized medicine enhances treatment efficacy while reducing adverse effects. This approach has gained traction due to the availability of advanced technologies that can rapidly analyze a patient's genetic and molecular profile. As personalized medicine gains prominence, the demand for biomarkers that guide treatment decisions will continue to grow. This is projected to expand the cancer biomarkers market scope.

Significant Technological Innovations

The advent of high-throughput techniques such as next-generation sequencing, mass spectrometry, and microarray analysis has exponentially increased our ability to identify and analyze potential biomarkers. These methods enable the identification of specific genetic mutations, epigenetic changes, and protein expression patterns that are indicative of different cancer types. Moreover, bioinformatics tools facilitate the interpretation of vast datasets, aiding in the discovery of novel biomarker candidates. These technological advancements not only expedite biomarker discovery but also enhance their sensitivity and specificity, making them more reliable for clinical use. As technology continues to evolve, it is anticipated that the pool of cancer diagnosis solutions will expand, further transforming the cancer biomarkers market outlook.

Cancer Biomarkers Industry Segmentation:

Breakup by Profiling Technology:

  • Omic Technologies
  • Imaging Technologies
  • Immunoassays
  • Cytogenetics

Omic technologies, encompassing genomics, proteomics, and metabolomics, play a pivotal role in cancer biomarker discovery and profiling. Genomic analysis reveals alterations in DNA sequences, identifying mutations and genetic variations associated with cancer development. Proteomics delves into the intricate world of proteins, identifying biomarkers by studying their expression levels, modifications, and interactions. Metabolomics focuses on small molecule metabolites, shedding light on metabolic pathways disrupted in cancer. These omic approaches provide a comprehensive understanding of the molecular intricacies underlying cancer, enabling the identification of potential biomarkers with high precision. Their ability to uncover subtle changes in genes, proteins, and metabolites makes omic technologies indispensable in the quest for reliable cancer biomarkers, enhancing diagnostic accuracy and paving the way for targeted therapies.

Techniques like positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) provide detailed anatomical and functional information. These technologies enable the visualization of tumors, their growth patterns, and interactions with surrounding tissues. Molecular imaging techniques, a subset of imaging technologies, utilize specific tracers to visualize molecular changes within tumors. This aids in identifying unique biomarkers expressed on cancer cells. Imaging-based biomarker profiling not only aids in accurate diagnosis but also assists in treatment planning and monitoring. As imaging technologies continue to advance, their role in non-invasive biomarker identification and real-time monitoring of treatment responses becomes increasingly integral.

Enzyme-linked immunosorbent assays (ELISA) and multiplex immunoassays measure the concentration of specific proteins, including biomarkers indicative of various cancers. Their high sensitivity and ability to analyze multiple analytes simultaneously make immunoassays invaluable in cancer diagnosis, prognosis, and therapeutic monitoring. Immunoassays are particularly well-suited for measuring soluble proteins and antigens present in blood or other bodily fluids. The advent of novel immunoassay platforms, such as bead-based and microfluidic systems, further enhances their capabilities. Immunoassay-based biomarker profiling not only aids in clinical decision-making but also expedites the development of targeted therapies by identifying patients likely to respond favorably to specific treatments.

Breakup by Biomolecule:

  • Genetic Biomarkers
  • Protein Biomarkers
  • Glyco-Biomarkers

Genetic biomarkers hold the largest share in the market

Genetic biomarkers offer insights into an individual's genetic predisposition, mutations, and variations that contribute to disease development. The advent of advanced genomic sequencing technologies has revolutionized our ability to decode the genetic code, identifying specific gene alterations associated with various cancers. Genetic biomarkers not only facilitate early cancer detection but also guide personalized treatment strategies. By pinpointing genetic mutations driving a particular cancer, clinicians can tailor therapies to target these specific genetic anomalies, thereby enhancing treatment efficacy while minimizing adverse effects. Moreover, genetic biomarkers play a crucial role in the development of precision medicine, where treatments are tailored to a patient's genetic profile.

Breakup by Cancer Type:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Others

Lung cancer dominates the market

Lung cancer holds a significant global prevalence, ranking among the leading causes of cancer-related deaths. The strong association between lung cancer and smoking, along with environmental factors, contributes to its widespread occurrence. Furthermore, advancements in diagnostic technologies, including imaging and molecular profiling, have improved lung cancer detection and classification. This has led to a higher number of diagnosed cases, contributing to the segment's prominence. Additionally, the complex nature of lung cancer, characterized by diverse subtypes like non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), necessitates targeted therapies based on biomarker profiles. This drives research and innovation, fostering the development of precision medicine approaches tailored to specific lung cancer subtypes.

Breakup by Application:

  • Diagnostics
  • Prognostics
  • Risk Assessment
  • Drug Discovery and Development
  • Others

Cancer biomarkers play a critical role in enabling early and accurate cancer detection. By identifying specific molecular signatures associated with various cancer types, biomarkers assist in pinpointing the presence of cancer at its initial stages. This facilitates timely intervention, ultimately leading to improved patient outcomes. Biomarker-based diagnostics encompass a range of techniques, including blood tests, imaging, and molecular assays, which collectively contribute to effective and non-invasive cancer detection.

By analyzing specific biomarkers, clinicians can gauge the aggressiveness of the cancer, assess the risk of recurrence, and estimate patient survival rates. These insights guide treatment planning, allowing for tailored therapies that match the anticipated disease trajectory. Prognostic biomarkers contribute to informed decision-making, enabling patients and healthcare providers to make choices aligned with individual prognosis.

These biomarkers enable early screening of individuals at elevated risk due to genetic, environmental, or lifestyle factors. By identifying those at risk, healthcare professionals can implement targeted surveillance, preventive measures, and lifestyle interventions to reduce the likelihood of cancer development. Risk management based on biomarkers empowers proactive healthcare strategies that emphasize prevention and early intervention.

Breakup by End User:

  • Hospitals
  • Academic and Research Institutions
  • Ambulatory Surgical Centers
  • Diagnostic Laboratories
  • Others

With their comprehensive range of medical services and infrastructure, hospitals serve as essential hubs for cancer diagnosis, treatment, and management. Biomarker-based tests are seamlessly integrated into hospital workflows, facilitating timely and accurate cancer diagnosis. Hospitals also offer the necessary facilities for patient monitoring and follow-up, making them central to cancer care. The demand for biomarkers in hospitals is driven by the need for efficient diagnostic tools that aid in early detection, prognosis, and treatment decision-making.

These institutions conduct in-depth research to identify and validate novel biomarkers, contributing to the expansion of our understanding of cancer biology. They also develop cutting-edge technologies and methodologies for biomarker discovery and analysis. Academic institutions serve as platforms for training the next generation of researchers, clinicians, and professionals who will drive biomarker-related research and applications. Additionally, academic collaborations often lead to the development of innovative diagnostic and therapeutic approaches, further enriching the biomarkers market.

These centers provide outpatient surgical and medical procedures, including cancer diagnostics and treatment. ASCs offer efficient and convenient options for patients who require biomarker-based tests, minimizing the need for hospitalization. They cater to patients seeking specialized care in a more streamlined and patient-centered environment. As the trend towards outpatient care continues to grow, ambulatory surgical centers are increasingly adopting biomarker-based diagnostic and treatment methods, contributing to their significance within the market ecosystem.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for cancer biomarkers.

North America possesses a well-established healthcare infrastructure with advanced medical facilities, research centers, and academic institutions. This provides a conducive environment for the integration of biomarker-based diagnostics and treatments into clinical practice. Additionally, substantial investments in cancer research and healthcare technology contribute to the continuous advancement of biomarker discovery and validation. This, coupled with a strong emphasis on personalized medicine, drives the demand for biomarker-driven approaches in patient care. Moreover, North America's proactive regulatory landscape, with agencies like the FDA, fosters the validation and approval of new biomarkers, ensuring their safety and efficacy. This regulatory support instills confidence among healthcare professionals and encourages the adoption of biomarker-based tests. Besides this, a higher awareness of cancer prevention, early detection, and treatment options within the population further fuels the demand for biomarker-based solutions. The presence of a substantial patient pool and a robust pharmaceutical industry also play a pivotal role in the region's dominance in the cancer biomarkers market.

Competitive Landscape:

Major players invest heavily in R&D to identify and validate new biomarkers. This involves extensive laboratory research, clinical trials, and collaborations with academic institutions to discover biomarkers that offer higher accuracy and specificity in cancer detection and monitoring. Additionally, collaboration between biotechnology firms, pharmaceutical companies, research institutions, and healthcare providers accelerates the translation of biomarker discoveries into practical applications. Partnerships facilitate the development of novel diagnostics and therapies that incorporate biomarker information. Other than this, key players continually innovate by adopting and developing cutting-edge technologies, such as next-generation sequencing, liquid biopsies, and advanced imaging techniques. These innovations enhance biomarker detection sensitivity, allowing for earlier and more accurate cancer diagnoses. Besides this, leading firms are focusing on developing companion diagnostics that identify patients most likely to respond to specific treatments. This approach optimizes treatment selection, leading to better patient outcomes and reduced healthcare costs. In line with this, key market players are driving the shift toward personalized medicine by utilizing biomarker information to tailor treatments to individual patients. This approach improves treatment efficacy and minimizes adverse effects. Furthermore, collaboration with regulatory authorities, such as the FDA, ensures that biomarker-based tests meet rigorous standards for accuracy and safety. Regulatory approvals enhance trust in these tests among healthcare professionals and patients.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Becton Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • General Electric Company
  • Illumina Inc.
  • Qiagen N.V.
  • Sino Biological Inc.
  • Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1.What was the size of the global cancer biomarkers market in 2024?
  • 2.What is the expected growth rate of the global cancer biomarkers market during 2025-2033?
  • 3.What are the key factors driving the global cancer biomarkers market?
  • 4.What has been the impact of COVID-19 on the global cancer biomarkers market?
  • 5.What is the breakup of the global cancer biomarkers market based on the biomolecule?
  • 6.What is the breakup of the global cancer biomarkers market based on the cancer type?
  • 7.What are the key regions in the global cancer biomarkers market?
  • 8.Who are the key players/companies in the global cancer biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Biomarkers Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Profiling Technology

  • 6.1 Omic Technologies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Imaging Technologies
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Immunoassays
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Cytogenetics
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Biomolecule

  • 7.1 Genetic Biomarkers
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Protein Biomarkers
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Glyco-Biomarkers
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Cancer Type

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Lung Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Colorectal Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Prostate Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Stomach Cancer
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Diagnostics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Prognostics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Risk Assessment
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Drug Discovery and Development
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Academic and Research Institutions
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Ambulatory Surgical Centers
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Diagnostic Laboratories
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Others
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Abbott Laboratories
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Agilent Technologies Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Becton Dickinson and Company
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 bioMerieux SA
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Danaher Corporation
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 F. Hoffmann-La Roche AG
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 SWOT Analysis
    • 16.3.7 General Electric Company
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Illumina Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Qiagen N.V.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Sino Biological Inc.
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
    • 16.3.11 Thermo Fisher Scientific Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Biomarkers Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Biomarkers Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Cancer Biomarkers Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Cancer Biomarkers Market: Breakup by Profiling Technology (in %), 2024
  • Figure 5: Global: Cancer Biomarkers Market: Breakup by Biomolecule (in %), 2024
  • Figure 6: Global: Cancer Biomarkers Market: Breakup by Cancer Type (in %), 2024
  • Figure 7: Global: Cancer Biomarkers Market: Breakup by Application (in %), 2024
  • Figure 8: Global: Cancer Biomarkers Market: Breakup by End User (in %), 2024
  • Figure 9: Global: Cancer Biomarkers Market: Breakup by Region (in %), 2024
  • Figure 10: Global: Cancer Biomarkers (Omic Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Cancer Biomarkers (Omic Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Cancer Biomarkers (Imaging Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Cancer Biomarkers (Imaging Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Cancer Biomarkers (Immunoassays) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Cancer Biomarkers (Immunoassays) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Cancer Biomarkers (Cytogenetics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Cancer Biomarkers (Cytogenetics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Cancer Biomarkers (Genetic Biomarkers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Cancer Biomarkers (Genetic Biomarkers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Cancer Biomarkers (Protein Biomarkers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Cancer Biomarkers (Protein Biomarkers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Cancer Biomarkers (Glyco-Biomarkers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Cancer Biomarkers (Glyco-Biomarkers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Cancer Biomarkers (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Cancer Biomarkers (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Cancer Biomarkers (Lung Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Cancer Biomarkers (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Cancer Biomarkers (Colorectal Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Cancer Biomarkers (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Cancer Biomarkers (Prostate Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Cancer Biomarkers (Prostate Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Cancer Biomarkers (Stomach Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Cancer Biomarkers (Stomach Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Cancer Biomarkers (Other Cancer Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Cancer Biomarkers (Other Cancer Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Cancer Biomarkers (Diagnostics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Cancer Biomarkers (Diagnostics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Cancer Biomarkers (Prognostics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Cancer Biomarkers (Prognostics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: Cancer Biomarkers (Risk Assessment) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Global: Cancer Biomarkers (Risk Assessment) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Global: Cancer Biomarkers (Drug Discovery and Development) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Global: Cancer Biomarkers (Drug Discovery and Development) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Global: Cancer Biomarkers (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Global: Cancer Biomarkers (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Global: Cancer Biomarkers (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Global: Cancer Biomarkers (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Global: Cancer Biomarkers (Academic and Research Institutions) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Global: Cancer Biomarkers (Academic and Research Institutions) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Global: Cancer Biomarkers (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Global: Cancer Biomarkers (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Global: Cancer Biomarkers (Diagnostic Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Global: Cancer Biomarkers (Diagnostic Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Global: Cancer Biomarkers (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Global: Cancer Biomarkers (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: North America: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: North America: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: United States: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: United States: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Canada: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Canada: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Asia-Pacific: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Asia-Pacific: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: China: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: China: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Japan: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Japan: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: India: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: India: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: South Korea: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: South Korea: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Australia: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Australia: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Indonesia: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Indonesia: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Europe: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Europe: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Germany: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Germany: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: France: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: France: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: United Kingdom: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: United Kingdom: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Italy: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Italy: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Spain: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 89: Spain: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Russia: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 91: Russia: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Others: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 93: Others: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Latin America: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 95: Latin America: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 96: Brazil: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 97: Brazil: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 98: Mexico: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 99: Mexico: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 100: Others: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 101: Others: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 102: Middle East and Africa: Cancer Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 103: Middle East and Africa: Cancer Biomarkers Market: Breakup by Country (in %), 2024
  • Figure 104: Middle East and Africa: Cancer Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 105: Global: Cancer Biomarkers Industry: SWOT Analysis
  • Figure 106: Global: Cancer Biomarkers Industry: Value Chain Analysis
  • Figure 107: Global: Cancer Biomarkers Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Biomarkers Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Cancer Biomarkers Market Forecast: Breakup by Profiling Technology (in Million USD), 2025-2033
  • Table 3: Global: Cancer Biomarkers Market Forecast: Breakup by Biomolecule (in Million USD), 2025-2033
  • Table 4: Global: Cancer Biomarkers Market Forecast: Breakup by Cancer Type (in Million USD), 2025-2033
  • Table 5: Global: Cancer Biomarkers Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 6: Global: Cancer Biomarkers Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 7: Global: Cancer Biomarkers Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: Cancer Biomarkers Market: Competitive Structure
  • Table 9: Global: Cancer Biomarkers Market: Key Players